<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146160">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717586</url>
  </required_header>
  <id_info>
    <org_study_id>OPRU Pravastatin</org_study_id>
    <nct_id>NCT01717586</nct_id>
  </id_info>
  <brief_title>Pravastatin for Prevention of Preeclampsia</brief_title>
  <official_title>Pravastatin for the Prevention of Preeclampsia in High-Risk Women: A Phase I Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this pilot study is to determine the pharmacokinetic (PK) parameters
      and collect preliminary safety data for pravastatin when used as a prophylactic daily
      treatment in pregnant women at high risk of preeclampsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preeclampsia shares pathogenic similarities with adult cardiovascular diseases as well as
      many risk factors. Endothelial dysfunction and inflammation are fundamental for the
      initiation and progression of both. There is strong evidence that
      3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are
      beneficial in primary and secondary prevention of cardiovascular mortality and other
      cardiovascular events. Biological plausibility as well as animal data supports a similar
      role for statins in preeclampsia.

      Currently, there are no clinically available agents to prevent preeclampsia. However because
      of the below properties of statins, this class of medications could substantially contribute
      to preeclampsia prevention.

        1. Statins pleiotropic actions on various mechanisms: reversing the angiogenic imbalance
           by upregulating vascular endothelial growth factor (VEGF) and placental growth factor
           (PlGF), and reducing the antiangiogenic factors such as soluble fms-like tyrosine
           kinase-1 (sFlt-1) and soluble endoglin (sEng).

        2. Statins up regulation of endothelial nitric oxide synthase, leading to improved nitric
           oxide production in the vasculature and to activate the heme oxygenase-1/carbon
           monoxide (HO-1/CO) pathway, protecting the endothelium and reducing the inflammatory
           and oxidative insults.

      The purpose of this pilot study is to evaluate the maternal-fetal safety and pharmacokinetic
      (PK) profiles of pravastatin when used in pregnant women at high-risk of developing
      preeclampsia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number and type of maternal adverse events</measure>
    <time_frame>From the date of randomization until the date of delivery, assessed up to 210 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The presence of side effects and adverse events will be assessed at each study visit by:
a symptoms checklist
any other report of adverse events
at select visits: laboratory testing for liver function test(LFT) and creatine kinase(CK)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and type of fetal/neonatal adverse events</measure>
    <time_frame>From date of birth up to discharge or 120 days after birth.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The presence of adverse events will be assessed by evaluating
Fetal and neonatal death
Birthweight (including rate of small for gestational age)
Apgar scores
Ponderal index
Congenital malformations
Auditory brainstem response (ABR) evoked potential
Cord blood lipid profile, AST/ALT, and CK levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of pravastatin sodium during pregnancy</measure>
    <time_frame>Between Pre-dose (0) and 24 hours post dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Timed blood and urine collection performed once between 18 wks 0 days GA and 23 wks 6 days GA and once between 30 wks 0 days GA and 33 wks 6 days GA.
Timed blood collection intervals: pre-dose(0)and 0.5hr, 1hr, 1.5hr, 2hr, 3hr, 4hr, 6hr, 8hr, 10hr, 12hr and 24hr post dose.
Time urine collection intervals: pre-dose (0) and 0-4hr, 4-8hr, 8-12hr, 12-24 hr post dose.
Evaluation parameters:Maximum observed plasma concentration (Cmax) and peak time (Tmax), Steady-state area under the plasma concentration-time curve during the 24-h dosing interval (AUC0-24h), Steady-state apparent oral clearance (CL/F), Elimination half-life (t½), Renal clearance of pravastatin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Pravastatin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregnant women at high-risk for preeclampsia who are taking pravastatin during their pregnancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pregnant women who are at high-risk for developing preeclampsia who are taking a placebo during their pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into two cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg.</description>
    <arm_group_label>Pravastatin Group</arm_group_label>
    <other_name>pravastatin sodium</other_name>
    <other_name>Brand name: Pravachol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented history (by chart review) of prior severe preeclampsia in either of the
             two pregnancies preceding the current one and requiring delivery at 34 weeks or less
             gestation.

          -  18 years or older with the ability to give informed consent

          -  Singleton pregnancy

          -  Normal serum transaminase (ALT and AST) concentrations in the last 6-months

          -  Gestational age (GA) between 12 weeks 0 days to 16 weeks 6 days based on clinical
             information and confirmed by an ultrasound per study procedures

        Exclusion Criteria:

          -  Known chromosomal, genetic, or major fetal malformations, fetal demise, or planned
             termination

          -  Multifetal gestation

          -  Patient with contraindications for statin therapy

               -  Hypersensitivity to pravastatin or any component of the product

               -  Active liver disease in the past 6 months (acute hepatitis, chronic    active
                  hepatitis) by medical history

               -  Unexplained elevations (1.5x normal) of serum transaminases persistent on
                  repeated laboratory testin in the 6 months before this visit

          -  Patients with any of the following conditions as it may predispose them to adverse
             events or side effects.

               -  Current (past month) heavy alcohol use defined as ≥2 drinks per day

               -  Illicit drug use

               -  Amyotrophic lateral sclerosis (ALS)

               -  Concomitant therapy with fibrates, niacin, cyclosporine, clarithromycin or
                  erythromycin

               -  Recent (&lt;6 months) history of liver disease or have unexplained elevated
                  transaminases or jaundice

               -  History of cholestasis of the liver in prior pregnancy

               -  Personal or family history of myopathy or rhabdomyolysis

          -  Statin use in current pregnancy or in the last month prior to pregnancy

          -  Patients with any of the following medical conditions as described in medical record
             or patient history:

               -  Pregestational diabetes mellitus

               -  HIV positive

               -  Status post solid organ transplant

               -  Chronic renal disease/insufficiency with baseline serum creatinine ≥1.5 mg/dL

               -  Epilepsy or other seizure disorder

               -  Uterine malformations

               -  Cancer

               -  Familial hypercholesterolemia

               -  Heart disease including prior myocardial infarction and prior cerebrovascular
                  accident

          -  Concurrent and chronic ( &gt; 6 months) use of medications with potential drug
             interactions with statins such as immunosuppressive drugs, gemfibrozil, niacin,
             erythromycin, itraconazole, cholestyramine, digoxin, rifampin (Patients will not be
             excluded if the drug has been discontinued)

          -  Inability to tolerate oral medications secondary to severe nausea and vomiting of
             pregnancy

          -  Participating in another intervention study that influences maternal and fetal
             morbidity and mortality

          -  Plans to deliver in a non-network site.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary D. Hankins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Caritis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary F. Hebert, PharmD, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Flockhart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maged Costantine, MD</last_name>
    <phone>409-772-1571</phone>
    <email>mmcostan@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Brown, MPH, DrPH</last_name>
    <phone>301-816-4626</phone>
    <email>lindabrown@rti.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haneline, MD</last_name>
      <phone>317-274-8916</phone>
      <email>lhanelin@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>David Flockhart, MD, PhD</last_name>
      <phone>317-630-8795</phone>
      <email>dflockha@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Flockhart, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Caritis, MD</last_name>
      <phone>412-641-4874</phone>
      <email>scaritis@mail.magee.edu</email>
    </contact>
    <contact_backup>
      <last_name>Raman Venkataramanan, PhD</last_name>
      <phone>412-648-8547</phone>
      <email>rv@pitt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steve Caritis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maged Costantine, MD</last_name>
      <phone>409-772-1571</phone>
      <email>mmcostan@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gary D. Hankins, MD</last_name>
      <phone>409-772-1957</phone>
      <email>ghankins@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gary D. Hankins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary F. Hebert, PharmD, FCCP</last_name>
      <phone>206-616-5016</phone>
      <email>mhebert@u.washington.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Easterling, MD</last_name>
      <phone>206-543-1521</phone>
      <email>easter@u.washington.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary F. Hebert, PharmD, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://opru.rti.org/</url>
    <description>Link is for OPRU home page</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>preeclampsia</keyword>
  <keyword>pravastatin</keyword>
  <keyword>Pravachol®</keyword>
  <keyword>statin</keyword>
  <keyword>high-risk pregnancy</keyword>
  <keyword>safety</keyword>
  <keyword>fetal morbidity and mortality</keyword>
  <keyword>maternal morbidity and mortality</keyword>
  <keyword>neonatal mortality</keyword>
  <keyword>premature delivery</keyword>
  <keyword>preemie</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
